Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Thyroid gland cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In addition to a group of tumorous cancers which attack the thyroid gland, a form of lymphoma which focuses on the thyroid is also sometimes seen in medical practice. There are four types of thyroid cancer in addition to thyroid lymphoma: medullary, follicular, papillary, and anaplastic.
Genetic amplification of IQGAP1 in cancer
ActiveUS9157123B2Diminish invasivenessReduce spreadOrganic active ingredientsSugar derivativesCell invasionFollicular thyroid cancer
We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain ?3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC), 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN ?4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knock-down of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation. Co-immunoprecipitation assay showed direct interaction of IQGAP1 with E-cadherin, a known invasion-suppressing molecule, which was upregulated when IQGAP1 was knocked down. IQGAP1, through genetic copy gain, plays an important role in the invasiveness of thyroid cancer and represents a useful prognostic marker and therapeutic target for this and other cancers.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Total-nutrient formula food for thyroid cancer
InactiveCN104256648AImprove intestinal adhesionPlay a role in colonizationVitamin food ingredientsInorganic compound food ingredientsNutritionImmunity
Owner:胡安然
Preparation of 131I-thyroid stimulating hormone (TSH) and application thereof
InactiveCN101787077ASimple preparation processStable markerRadioactive preparation carriersDepsipeptidesTyrosineUndifferentiated Thyroid Tumor
The invention relates to the preparation of 131I-thyroid stimulating hormone (TSH) and an application thereof, belonging to the field of radionuclide therapeutic drugs. The compound 131I-thyroid stimulating hormone is a radioiodine marker for thyroid stimulating hormone with pathoclisis in vivo acting on thyrocyte. A preparation method of the 131I-thyroid stimulating hormone comprises the following steps of: carrying out iodine 131 marking on the thyroid stimulating hormone by utilizing a chloramine-T method, a peroxide oxidation method or an iodogen method, and introducing radionuclide iodine 131 for treatment into tyrosine residues in thyroid stimulating hormone molecules. The marking rate of the prepared 131I-TSH is 85.9 percent, the radiochemical purity after purification achieves more than 90 percent, and the prepared 131I-TSH can be stored stably for more than one week at room temperature; the 131I-TSH is mainly metabolized through the liver and excreted through the kidneys; the percentage of ID / g of the 131I-TSH in the thyroid gland is not obviously reduced in four hours; and the 131I-TSH can be concentrated in thyroid gland issues sealed by an iodine solution. Concerning low / undifferentiated thyroid tumours incapable of iodine uptake, the 131I-TSH can increase the radioiodine uptake of thyroid gland cancer cells, and the radioiodine 131 can be chosen for treatment.
Owner:JIANGSU INST OF NUCLEAR MEDICINE
Biomarker for preoperative identification of benign and malignant thyroid nodules, kit and application thereof
ActiveCN112684048AIncreased sensitivityImprove featuresComponent separationThyroid gland cancerBlood plasma
The invention relates to a biomarker for preoperative identification of benign and malignant thyroid nodules, a kit and application thereof. The level of 17 metabolites in peripheral blood plasma of a thyroid nodule patient is detected through metabonomics analysis, and omics analysis and a machine learning method are combined to construct a diagnosis model and evaluate the thyroid cancer diagnosis efficiency by using a subject working curve (ROC). The area of the metabolic marker combination diagnosis model composed of the metabolites under the ROC curve in thyroid nodule diagnosis can reach 95.05%, the sensitivity and specificity are both higher than 88%, and the metabolite marker combination diagnosis model can be applied to identification of thyroid benign and malignant nodules.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Implant agent treating for solid tumor
InactiveCN101204365ABoron compound active ingredientsPharmaceutical delivery mechanismNervous systemProstate cancer
The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.
Owner:JINAN SHUAIHUA PHARMA TECH
RNA antagonist compounds for the inhibition of apo-b100 expression
InactiveUS20090118213A1Lower Level RequirementsOrganic active ingredientsSugar derivativesIntestinal structureSpinal cord
Oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with either overexpression of Apo-B100, expression of mutated Apo-B100 or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
Owner:SANTARIS PHARMA AS
Mannan-binding lectin (MBL) in the treatment of immunocompromised conditions asssociated with cancer
The present invention pertains to the use of subunits and oligomers of mannan- binding lectin (MBL) in prophylactic and / or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease.
Owner:内蒂穆恩公司
Culture medium, culture method and detection method of thyroid cancer organoid
PendingCN112831471AEfficient formationImprove the success rate of cultivationCell dissociation methodsMicrobiological testing/measurementThyroid gland cancerCryopreservation
The invention provides a culture medium, a culture method and a detection method of a thyroid cancer organoid, the culture medium comprises a basic culture medium, B-27, N-acetylcysteine, nicotinamide, R-spondin 1 recombinant protein and other components, the culture medium has high thyroid cancer organoid culture success rate, high passage frequency, and good passage stability after repeated cryopreservation and resuscitation; the thyroid cancer organoid obtained by adopting the culture medium and the culture method is high in reducibility; and the detection method is comprehensive and accurate.
Owner:THE SECOND PEOPLES HOSPITAL OF SHENZHEN
Thyroid cancer pathological image classification method based on deep learning
ActiveCN112364920AEasy to classifySolve the problem of losing a large number of featuresCharacter and pattern recognitionNeural architecturesThyroid gland cancerThyroid pathology
The invention discloses a thyroid cancer pathological image classification method based on deep learning, and mainly solves the problem of poor thyroid cancer pathological image classification effectof an existing method. According to the implementation scheme, the method comprises the following steps: reading a thyroid pathology image database, extracting low-level convolution and pooling features by a receptive field network, and fusing the features to obtain fused low-level features; extracting high-level features, namely predicted category vectors, from the fused low-level features through a capsule network; updating the category vector through a dynamic routing algorithm to obtain a final category vector, and calculating the modulus of the category vector through a compression activation function; carrying out image reconstruction on the vector with the maximum modulus value through a decoding reconstruction network; iteratively updating weights in the receptive field network andthe capsule network to complete model training; and finally, inputting a thyroid pathological image to be classified into the trained model to obtain a final classification result. The invention improves the classification accuracy of the thyroid cancer pathological images and can be used for computer-aided diagnosis.
Owner:XIDIAN UNIV
Identification model for benign and malignant thyroid tumors and application thereof
The invention relates to a methylation marker for identification of benign and malignant thyroid tumors and evaluation of follicular tumors with uncertain malignant potential, and a method for constructing an identification model for benign and malignant thyroid tumors. The method comprises the following steps of: (1) acquiring the methylation levels of candidate sites or fragments in genome DNAsof a tumor sample and a control sample; (2) processing the methylation levels of the sites or fragments by using at least one algorithm selected from a group consisting of mhl, mhl3, umhl and pdr; (3)screening out a site or fragment having significant difference between the processed methylation level of the tumor sample and the processed methylation level of the control sample, and screening outan optional corresponding algorithm, wherein the site or fragment is the methylation marker; and (4) constructing the model for identifying benign and malignant thyroid cancer according to the processed methylation levels of the methylation marker.
Owner:SINGLERA GENOMICS (SHANGHAI) LTD
Application of MIT and/or DIT as thyroid cancer markers and kit
ActiveCN112162050AImprove featuresImprove effectivenessComponent separationThyroid Gland TissueThyroid gland cancer
Owner:PEKING UNIV
22-nor-stigmasta thiosemicarbazone compound and preparing method and application thereof
InactiveCN105859821AGood inhibitory effectNon-cytotoxicSteroidsAntineoplastic agentsCancer cellCytotoxicity
The invention discloses a 22-nor-stigmasta thiosemicarbazone compound and a preparing method and application thereof. The structural formula of the 22-nor-stigmasta thiosemicarbazone compound is shown in the description. In vitro cancer cell growth and proliferation activity inhibition tests show that the prepared 22-nor-stigmasta thiosemicarbazone compound has a remarkable inhibition effect on various tumor cell strains such as human nipple thyroid gland cancer cells, human oral cavity epidermoid carcinoma cells and cervical cancer. Meanwhile, the 22-nor-stigmasta thiosemicarbazone compound is free of cytotoxicity on human kidney epithelial cells (HEK293T) and can be used for preparing medicine for treating cancer.
Owner:南宁师范大学
Oligomeric compounds for the modulation of survivin expression
Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
Owner:圣塔里斯·法尔马公司 +1
Medicinal composition for treating Hashimoto's thyroiditis, and preparation method and use thereof
ActiveCN107158084AClear treatment effectCraft economyImmunological disordersEndocrine system disorderIn vivoActive ingredient
The invention belongs to the fields of traditional Chinese medicines and natural medicine pharmaceuticals, and concretely relates to a medicinal composition for treating Hashimoto's thyroiditis, and a preparation method and a use thereof. The medicinal composition for treating Hashimoto's thyroiditis comprises, by weight, 1 part of snakegourd peel and 1-20 parts of dried figs. The snakegourd peel and the dried figs are preferably selected according to the above weight proportions, and are processed through steps to prepare polysaccharide extract, and pharmaceutically-acceptable or health product-acceptable auxiliary materials are added to prepare a conventional oral preparation. A result of experiments of in vivo and in vivo anti-thyroid cancer pharmacological effects of the extract shows that the polysaccharide extract can reduce the high-titer autoantibodiesTGAb and TPOAb of HT, reduce IL-2, increase IL-4, inhibit the hyperthyroidism of Th1 cell functions and promote the drift of Th1 to Th2 in order to alleviate the Hashimoto's thyroiditis.
Owner:SICHUAN UNIV
Product and method for identifying, diagnosing and evaluating thyroid cancer
The invention discloses a product and a method for identifying, diagnosing and evaluating thyroid cancer. In the specific embodiment of the invention, IgG in body fluid is separated, then N-carbohydrate chains on IgG are dissociated through glycosidase, and the expression quantity difference of the N-carbohydrate chains on IgG in thyroid cancer and non-cancer control (healthy and benign nodule) body fluid is compared by utilizing a mass spectrum-based analysis method. The inventor finds that compared with non-cancer control, the expression quantities of three N sugar chains (H3N5F1, H4N5F1 and H5N5F1) in plasma of a thyroid cancer patient are respectively and obviously increased, meanwhile the other N sugar chain H4N4F1 is obviously reduced. That is to say, differently expressed IgG N-carbohydrate chain can effectively distinguish thyroid cancer and non-cancer control, and the combination of H3N5F1, H4N5F1 and H5N5F1 also has the potential of early diagnosis of thyroid cancer. The method is high in sensitivity, a required blood sample is easy to obtain, the accuracy is high when the method is used for thyroid cancer differential diagnosis, and the method has important application value.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Sugar chain marker for predicting postoperative recurrence of thyroid cancer and application thereof
ActiveCN114660290AComponent separationMaterial analysis by electric/magnetic meansThyroid gland cancerOncology
The invention discloses a sugar chain marker for predicting postoperative recurrence of thyroid cancer and application of the sugar chain marker, and particularly, the sugar chain marker comprises H4N3F1L1 and / or H4N6F1E1. The expression quantities of the markers have significant differences in healthy human bodies, thyroid cancer, thyroid cancer postoperative follow-up visit periods and thyroid cancer postoperative recurrence patients, so that the markers can be used for distinguishing the thyroid cancer patients from healthy people, and can also be used for distinguishing non-recurrence people and postoperative recurrence people after the thyroid cancer operation; the potential of predicting the postoperative recurrence of the thyroid cancer is realized.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Chimeric antigen receptors and compositions and methods of use thereof
InactiveUS20200016201A1Growth inhibitionAntibody mimetics/scaffoldsReceptors for hormonesAntigen receptorsThyroid gland cancer
Owner:UNIV OF SOUTHERN CALIFORNIA
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
ActiveUS11279675B2Reduce molecular weightRaise the ratioOrganic chemistry methodsAntineoplastic agentsQuinolineThyroid gland cancer
![Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b96c8405-52a1-42db-a9fd-0430669e206c/US11279675-D00001.png "Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use")
![Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b96c8405-52a1-42db-a9fd-0430669e206c/US11279675-D00002.png "Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use")
![Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b96c8405-52a1-42db-a9fd-0430669e206c/US11279675-D00003.png "Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use")
Owner:EXELIXIS INC
Thyroid cancer diagnosis prognostic marker MAPK8IP1P2 and application thereof
ActiveCN111269987AInhibit tumorigenesis in vivoMicrobiological testing/measurementAntineoplastic agentsNode metastasisCancer cell
It is found for the first time that down-regulation is conducted in thyroid cancer tissues, down-regulation is more obvious in thyroid cancer tissues with lymph node metastasis, MAPK8IP1P2 down-regulation indicates poor prognosis of thyroid cancer patients, and overexpression of MAPK8IP1P2 can inhibit in-vivo tumorigenesis of thyroid cancer cells. Based on the new discovery, the MAPK8IP1P2 can beused for diagnosing whether a subject suffers from thyroid cancer or not, lymph node metastasis of thyroid cancer and survival prognosis, thyroid cancer tumorigenesis is inhibited through the medicinefor overexpression of the MAPK8IP1P2, and a new strategy is provided for diagnosis, prognosis and treatment of the thyroid cancer.
Owner:吉林大学中日联谊医院
Application of human SHCBP1 gene and related product
ActiveCN110791566APrevent proliferationInhibit apoptosisOrganic active ingredientsMicrobiological testing/measurementCancer cellThyroid gland cancer
The invention belongs to the field of biological medicine research, and particularly relates to application of a human SHCBP1 gene used as a target in preparing a thyroid cancer treatment medicine orpreparing a thyroid cancer diagnosis medicine. Through the broad and deep research, the invention discovers that after the expression of the human SHCBP1 gene is down-regulated by adopting an RNAi method, the multiplication of thyroid cancer cells can be effectively inhibited, the cell apoptosis is promoted, and the growth process of thyroid cancer can be effectively controlled. The siRNA or a nucleic acid building body and a slow virus containing the siRNA can specifically inhibit a multiplication capacity of the thyroid cancer cells, inhibit a tumor formation capacity of the thyroid cancer cells in a human body, promote the thyroid cancer cell apoptosis, inhibit the cloning of the thyroid cancer cells, inhibit a thyroid cancer cell metastasis capacity, inhibit a thyroid cancer cell transfer capacity and change the period distribution of the thyroid cancer cells so as to treat the thyroid cancer, so that a new direction is opened for thyroid cancer treatment.
Owner:XUZHOU CENT HOSPITAL
Micromolecular metabolite atlas as well as producing method and application thereof
InactiveCN102565253AHigh sensitivityImprove throughputComponent separationHydroxybutyric acidMetabolite
The invention relates to the technical field of medical diagnostics, in particular to a blood micromolecular metabolite atlas for identifying papillary thyroid cancer, benign goiter or normal person, and a producing method thereof. The micromolecular metabolite comprises two blood metabolism markers, namely sphinganine 1-phosphate and hydroxybutyric acid which respectively have molecular weight of 453.2855 and 569.3481 as well as corresponding ions detected by mass spectroscopy of 454.2928 and 570.3547. Clinical experiment proves that the atlas has thyroid cancer judgment accuracy rate of 82% and non-cancer (benign goiter and normal person) judgment accuracy rate of 75.3%. The method provided by the invention has the advantages of high sensitivity and high flux, overcomes the defect that a non-invasive diagnosis method for diagnosing benign and malignant thyroid tubercle is lacking clinically at present, and is suitable for screening and assistant diagnosis of thyroid cancer.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Application of ethanone compound in preparation of medicine for treating tumors
ActiveCN111603466APrevent proliferationPromote apoptosisOrganic active ingredientsAntineoplastic agentsDiseasePancreas Cancers
The invention discloses an application of 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indole-3-yl) ethanone or pharmaceutically acceptable salt thereof in preparation ofa medicine for treating or preventing tumor diseases. The product is used for relieving and / or adjunctively treating and / or treating myeloma, leukemia, lymphoma, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, lung cancer, liver cancer, skin cancer, rectal cancer, prostate cancer, thyroid cancer and other tumors. The 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3-yl) ethanone has a remarkable specific inhibition effect on PI3K gamma (polyisocyanurate).
Owner:JIANGNAN UNIV
Endoscopic thyroid hanging tool
PendingCN111150439ASimple structureReduces stretch injuriesDiagnosticsSurgeryEngineeringThyroid gland cancer
The invention discloses an endoscopic thyroid hanging tool. According to the endoscopic thyroid hanging tool, the problem that no sufficient space for a surgery is provided during lymph node dissection of a thyroid cancer lateral neck region in the prior art is mainly solved. The endoscopic thyroid hanging tool comprises a hanger and a suction pipe, wherein the hanger is of a non-sealed frameworkstructure, is used for separating flaps in a lateral neck region in a hanging manner so as to establish a cavity and comprises a first transverse plate, a vertical plate and a second transverse plate,the first transverse plate is transversely arranged, the vertical plate is connected with the first transverse plate and is vertically arranged at one end of the first transverse plate, and the second transverse plate is connected with the vertical plate and is inserted into the lateral neck region; and the suction pipe is arranged on the second transverse plate. The endoscopic thyroid hanging tool has the technical effects that traction injury of skin at a notch is little, postoperative hyperplasia of a notch scar is reduced, the structure is simple, and mounting is convenient.
Owner:沈祥
Traditional Chinese medicine composition for treating thyroid cancer and preparation method thereof
ActiveCN114177244AExact therapeutic effectGrowth inhibitionPharmaceutical delivery mechanismAntineoplastic agentsMedicinal herbsCancer cell
The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating thyroid cancer and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following nine raw medicinal materials: astragalus membranaceus, bighead atractylodes rhizome, poria cocos, white paeony root, prepared arisaema consanguineum schott, thunberg fritillary bulb, pinellia ternate, oroxylum indicum and selfheal, and has the effects of invigorating spleen and replenishing qi, eliminating dampness and phlegm, and softening hardness to dissipate stagnation. Pharmacodynamic experiment results show that the traditional Chinese medicine composition disclosed by the invention can obviously inhibit the growth of human thyroid cancer tumors in nude mice bearing tumors and obviously inhibit the proliferation of thyroid cancer cells in vitro, has an exact treatment effect on thyroid cancer, and provides a new clinical medication choice for patients.
Owner:ZHEJIANG PROVINCIAL PEOPLES HOSPITAL
Combinations of AHR inhibitor and PD1 inhibitor antibodies and their use in treatment of cancer
The present invention relates to a combination of at least two components, component A and component B, component A being an AhR inhibitor and component B being pemmumab or Nasumab. Another aspect of the invention relates to a combination of three components, component A, component B and component C; the component A is an AhR inhibitor, the component B is pemmumab or Nasumab, and the component C is another agent. The invention further relates to the use of such a combination as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, the compounds are useful in the treatment or prevention of breast cancer, respiratory tract cancer, brain cancer, reproductive organ cancer, digestive tract cancer, urinary tract cancer, eye cancer, liver cancer, skin cancer, kidney cancer, head and neck cancer, thyroid cancer, parathyroid cancer, and their distal metastases, lymphoma, sarcoma and leukemia.
Owner:BAYER AG
Material for adsorbing iodine in water body
ActiveCN111318273AOther chemical processesWater contaminantsEnvironmental engineeringThyroid gland cancer
The hypothyroidism, autoimmune thyroidism, papillary thyroid cancer and the like can be caused by excessive iodine ingested by a human body. At present, some water bodies in China have a certain degree of iodine pollution and greatly exceed the water body environment quality standard. The invention synthesizes a material for adsorbing iodine molecules in a water body, and the material has relatively large adsorption capacity for iodine molecules in water.
Owner:深圳深态环境科技有限公司
Cladribine sustained-release implantation agent for treating solid tumors
InactiveCN101219104AOrganic active ingredientsPharmaceutical delivery mechanismCarcinosarcomaToxic reaction
The invention relates to a sustained-release implant for treating solid tumors, which is characterized in that the sustained-release implant contains Cladribine and sustained-release excipient of effective anticancer amount. The solid tumors comprise brain tumor, liver cancer, lung cancer, esophageal cancer, carcinoma ventriculi, mammary cancer, pancreatic cancer, cancerous goiter, nasopharyngeal darcinoma, oophoroma, endometrial carcinoma, carcinoma of uterine cervix, renal carcinoma, prostatic carcinoma, carcinoma of urinary bladder, carcinoma of colon, rectal cancer, cutaneum carcinoma, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma from peripheral nervous system, mucosa, body of gland, blood vessel, bone tissue and absorbent gland. The sustained-release excipient is mainly degradable high molecular polymer with biological capacitability, and carmustine is slowly released into local tumor during the degradation and absorption process, therefore the invention not only obviously reduces the toxic reaction to the whole body, but also maintains effective drug concentration at the local tumor. The sustained-release implant is arranged in the local tumor, which not only reduces the carmustine toxic reaction to the whole body, but also increases the drug concentration at the local tumor selectively, thereby improving treatment effect of chemotherapeutics, radiotherapeutics and other non-operative treatment.
Owner:SHANDONG LANJIN PHARMA +1
Evaluation system based on thyroid cancer lymph node metastasis prediction model
PendingCN114694836AAccurate assessmentGuide standardized diagnosis and treatmentHealth-index calculationDrug and medicationsThyroid gland cancerOncology
The invention relates to an evaluation system based on a thyroid cancer lymph node metastasis prediction model. The evaluation system comprises a follow-up evaluation subsystem; the follow-up assessment subsystem comprises a preoperative patient follow-up assessment module and / or a postoperative patient follow-up assessment module; the preoperative patient follow-up assessment module comprises the following sub-modules: a first information collection module for collecting preoperative patient information data and sending the collected preoperative patient information data to a first risk processing module; according to the evaluation method based on the thyroid cancer lymph node metastasis prediction model and the follow-up visit system provided by the invention, preoperative lymph node metastasis risk evaluation can be effectively and accurately carried out on a patient; the evaluation method based on the thyroid cancer lymph node metastasis prediction model and the follow-up visit system provided by the invention can more effectively guide postoperative standardized diagnosis and treatment of a patient.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
Markers and their applications for the diagnosis, stratification and prognosis of thyroid cancer
ActiveCN113311079BEasy to detectShort timeAnalysing fluids using sonic/ultrasonic/infrasonic wavesComponent separationNode metastasisThyroid gland cancer
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com